Skip to search formSkip to main contentSkip to account menu

SCH-530348

Known as: SCH 530348, SCH530348 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

vorapaxar

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
The PAR 1 antagonist , SCH 79797 , alters platelet morphology and function indepen-dently of PARs
doi:10.1160/TH12-06-0389 Thromb Haemost 2013; 109: 164–167 Dear Sirs, Protease-activated receptors (PARs) are a family of four G… 
2015
2015
Bacterial Pulmonary Infection Proteinase-Activated Receptor 1 during Regulation of Neutrophilic Inflammation by Chambers
Neutrophils are key effector cells of the innate immune response to pathogenic bacteria, but excessive neutrophilic inflammation… 
2010
2010
Identification of Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of SCH 530348 (Vorapaxar), a Potent Oral Thrombin (PAR1) Receptor Antagonist
Vorapaxar (SCH 530348), a potent oral thrombin receptor (PAR-1) antagonist, is being developed as an antiplatelet agent for… 
2010
2010
Évaluation pré-clinique et clinique de deux nouvelles stratégies dans le traitement des maladies cardiovasculaires : activité anti-thrombotique de l'inhibition du récepteur P2Y1 et activité anti…
Alors que la plaquette a un role preponderant dans le maintient de l'hemostase, son implication dans la formation de la thrombose… 
2009
2009
4. Clinical Perspectives of New Antiplatelet Drugs
Previous studies clearly demonstrated the efficacy of antiplatelet drugs for secondary prevention of atherothrombosis in patients… 
2009
2009
Gateways to clinical trials.
ABT-869, Acadesine, Acetylsalicylic acid/omeprazole, Adefovir, Adefovir dipivoxil, AEG-35156, Agatolimod sodium, Albiglutide… 
2009
2009
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2009
2009
Nové protidestičkové léky v léčbě kardiovaskulárních chorob
Protidestickova lecba je zakladnim lecebným postupem v prevenci i lecbě kardiovaskularnich onemocněni. Nicmeně dostupne postupy… 
2008
2008
Gateways to clinical trials. July-August 2008.
(-)-Epigallocatechin gallate, 501516, 89-12; Abatacept, Adalimumab, Adefovir dipivoxil, AG-701, Agatolimod sodium, Alefacept… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)